Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044833
Filing Date
2024-11-12
Accepted
2024-11-12 17:08:24
Documents
81
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2258529
2 ex31-1.htm EX-31.1 18285
3 ex31-2.htm EX-31.2 18124
4 ex32-1.htm EX-32.1 7494
5 ex32-2.htm EX-32.2 7818
  Complete submission text file 0001493152-24-044833.txt   12209269

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cldi-20240930.xsd EX-101.SCH 89776
7 XBRL CALCULATION FILE cldi-20240930_cal.xml EX-101.CAL 80882
8 XBRL DEFINITION FILE cldi-20240930_def.xml EX-101.DEF 445484
9 XBRL LABEL FILE cldi-20240930_lab.xml EX-101.LAB 734794
10 XBRL PRESENTATION FILE cldi-20240930_pre.xml EX-101.PRE 569866
85 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 2071835
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40789 | Film No.: 241449750
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)